N4 Pharma Share Discussion Threads

[nobbygnome] 22/1/2019 16:50

Yes it's the lack of any 'IMHO' which is the telling part....... I always try to be polite but his posting is nothing short of disgraceful. Personally I think it is based on complete naivety and his fawning relationship with his beloved Nigel😘....

[ih_575893] 22/1/2019 16:43

Mystic bell end hugh is back. Ahhhhh

[fireball xl5] 22/1/2019 16:27

Oh, your back with your hackles up dp, you just can't resist Hugh lol!

[hughwilson] 22/1/2019 13:47

Possibly, although a straight takeover is just as likely.
Five AIM companies were taken over last year because of their technology.

[escapetohome] 21/1/2019 23:01

There is some life in this share after all!

Come on n4p!!

I still have a few.

[jimbobaroony] 21/1/2019 21:39

Wow, then I should buy a load more then.

[pol123] 21/1/2019 20:24

Yep, nothing wrong with your eyes :-0

[jimbobaroony] 20/1/2019 23:37

Really pol? That is fascinating. News within 2 weeks?

[pol123] 19/1/2019 20:15

If we get a deal penned we will move swiftly,for sure. 50p not out of the question....news within 2 weeks :-)

[cf456] 18/1/2019 14:01

No probs.

Price pushing up again by the looks of it.

[ivor hunch] 18/1/2019 12:42

cf456 Interesting analysis - very encouraging. Thanks for posting.

[ch1rp] 17/1/2019 16:51

If this bounces back up a third time it WILL ROCKET:)))

[cf456] 17/1/2019 11:59

The share price can certainly move very quickly when it gets going:

"we would point out that the share price rally in the first two months of 2018 that saw the shares move from under 10p to as high as 35p was almost exclusively driven by announcements relating to positive progress being made with Nuvec. Moreover, subsequent progress with Nuvec has been hugely positive."

Worth watching closely for the next leg up.

[cf456] 17/1/2019 09:37

First Equity - Top 10 Micro-Cap Picks for 2019

"We believe that the shares are currently materially undervalued, with the wider market having failed to appreciate the potential value of Nuvec."

"We are of the opinion that the current share price offers an incredibly attractive entry into a biotechnology that has genuine potential to make a real impact on the rapidly growing vaccines and therapeutics space."

[cyberbub] 15/1/2019 09:13

£10M market cap is too low for Nuvec's potential IMO. I bought a few yesterday and hope to see 20p soon.GLA NAI

[flashheart] 15/1/2019 08:45

N4P was always going to be about Nuvec and Nuvec it is!

[ch1rp] 14/1/2019 17:17

N 4 LET GO!

[jimbobaroony] 14/1/2019 14:14

low volumes

[flashheart] 14/1/2019 13:21

Indeed. Wakey wakey all!

[cyberbub] 11/1/2019 16:28

Just looking back in here, the chart is looking very much like it's ready for another leg up IMO... what likely news is coming up, please? Ta.

[remarkomsoc] 09/1/2019 12:15

that is a lotta cash

[remarkomsoc] 09/1/2019 12:04

In 2019, Moderna expects to start its first clinical trial on an mRNA therapy for a rare disease and expand its work in cancer, milestones Bancel expects to change the conversation around the company.

So why aren’t investors buying into the vision?

“You need to ask them,” Bancel said with a laugh, adding that Moderna’s complexity — it has 11 projects in human trials and 10 more waiting in the wings — might be befuddling to outsiders.

But investors who spoke to STAT pointed to two sticking points: Moderna is yet to rule out the lingering risks tied to mRNA, and, even at its depressed valuation, the company is simply too expensive.

Regardless of its short-term stock price, the post-IPO Moderna is sitting on $1.7 billion of cash, a sum that gives it at least three years of runway to change minds on Wall Street.